## Kara N Maxwell

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1529317/publications.pdf

Version: 2024-02-01

62 3,532 24 52 papers citations h-index g-index

66 66 66 6174 all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Breast and Prostate Cancer Risks for Male <i>BRCA1</i> and <i>BRCA2</i> Pathogenic Variant Carriers Using Polygenic Risk Scores. Journal of the National Cancer Institute, 2022, 114, 109-122.	3.0	19
2	Association of Inherited Mutations in DNA Repair Genes with Localized Prostate Cancer. European Urology, 2022, 81, 559-567.	0.9	17
3	Clinical and Functional Significance of TP53 Exon 4–Intron 4 Splice Junction Variants. Molecular Cancer Research, 2022, 20, 207-216.	1.5	4
4	Performance of polygenic risk scores for cancer prediction in a racially diverse academic biobank. Genetics in Medicine, 2022, 24, 601-609.	1.1	13
5	Inherited TP53 Variants and Risk of Prostate Cancer. European Urology, 2022, 81, 243-250.	0.9	40
6	<i>PTEN</i> Loss and <i>BRCA1</i> Promoter Hypermethylation Negatively Predict for Immunogenicity in BRCA-Deficient Ovarian Cancer. JCO Precision Oncology, 2022, 6, e2100159.	1.5	4
7	The distinct impacts of race and genetic ancestry on health. Nature Medicine, 2022, 28, 890-893.	15.2	16
8	Association Between Up-front Surgery and Risk of Stroke in US Veterans With Oropharyngeal Carcinoma. JAMA Otolaryngology - Head and Neck Surgery, 2022, 148, 740.	1.2	9
9	Abstract 2237: Rates of intervention after initial versus subsequent whole-body MRI screening in Li-Fraumeni Syndrome. Cancer Research, 2022, 82, 2237-2237.	0.4	O
10	Rates of COVID-19–Related Outcomes in Cancer Compared With Noncancer Patients. JNCI Cancer Spectrum, 2021, 5, pkaa120.	1.4	26
11	CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer. Nature Medicine, 2021, 27, 1280-1289.	15.2	365
12	SARS-CoV-2 Seropositivity and Seroconversion in Patients Undergoing Active Cancer-Directed Therapy. JCO Oncology Practice, 2021, 17, e1879-e1886.	1.4	2
13	A Natural Language Processing–Assisted Extraction System for Gleason Scores: Development and Usability Study. JMIR Cancer, 2021, 7, e27970.	0.9	1
14	EUS-based Pancreatic Cancer Surveillance in <i>BRCA1/BRCA2/PALB2/ATM</i> Carriers Without a Family History of Pancreatic Cancer. Cancer Prevention Research, 2021, 14, 1033-1040.	0.7	5
15	Analysis of the Li-Fraumeni Spectrum Based on an International Germline <i>TP53</i> Variant Data Set. JAMA Oncology, 2021, 7, 1800.	3.4	55
16	A Rare <i>TP53</i> Mutation Predominant in Ashkenazi Jews Confers Risk of Multiple Cancers. Cancer Research, 2020, 80, 3732-3744.	0.4	32
17	Mutation Rates in Cancer Susceptibility Genes in Patients With Breast Cancer With Multiple Primary Cancers. JCO Precision Oncology, 2020, 4, 916-925.	1.5	9
18	The relationship between circulating lipids and breast cancer risk: A Mendelian randomization study. PLoS Medicine, 2020, 17, e1003302.	3.9	63

#	Article	IF	CITATIONS
19	Upper Gastrointestinal Cancer Risk and Surveillance Outcomes in Li-Fraumeni Syndrome. American Journal of Gastroenterology, 2020, 115, 2095-2097.	0.2	9
20	Suggested application of HER2+ breast tumor phenotype for germline <i>TP53</i> variant classification within ACMG/AMP guidelines. Human Mutation, 2020, 41, 1555-1562.	1.1	16
21	XAF1 as a modifier of p53 function and cancer susceptibility. Science Advances, 2020, 6, eaba3231.	4.7	37
22	Frequency of radiation-induced malignancies post-adjuvant radiotherapy for breast cancer in patients with Li-Fraumeni syndrome. Breast Cancer Research and Treatment, 2020, 181, 181-188.	1.1	36
23	Positron Emission Tomography Imaging of Poly–(Adenosine Diphosphate–Ribose) Polymerase 1 Expression in Breast Cancer. JAMA Oncology, 2020, 6, 921.	3.4	26
24	Genomic landscape of metastatic breast cancer identifies preferentially dysregulated pathways and targets. Journal of Clinical Investigation, 2020, 130, 4252-4265.	3.9	61
25	The relationship between circulating lipids and breast cancer risk: A Mendelian randomization study. , 2020, 17, e1003302.		0
26	The relationship between circulating lipids and breast cancer risk: A Mendelian randomization study. , 2020, $17$ , e $1003302$ .		0
27	The relationship between circulating lipids and breast cancer risk: A Mendelian randomization study. , 2020, 17, e1003302.		0
28	The relationship between circulating lipids and breast cancer risk: A Mendelian randomization study. , 2020, $17$ , e $1003302$ .		0
29	The relationship between circulating lipids and breast cancer risk: A Mendelian randomization study. , 2020, 17, e1003302.		0
30	The relationship between circulating lipids and breast cancer risk: A Mendelian randomization study. , 2020, 17, e1003302.		0
31	The relationship between circulating lipids and breast cancer risk: A Mendelian randomization study. , 2020, 17, e1003302.		0
32	Reply. Gastroenterology, 2019, 157, 264-265.	0.6	0
33	Research participants' experiences with return of genetic research results and preferences for webâ€based alternatives. Molecular Genetics & Enomic Medicine, 2019, 7, e898.	0.6	24
34	Genomic Signatures Predict the Immunogenicity of BRCA-Deficient Breast Cancer. Clinical Cancer Research, 2019, 25, 4363-4374.	3.2	60
35	Identification and Confirmation of Potentially Actionable Germline Mutations in Tumor-Only Genomic Sequencing. JCO Precision Oncology, 2019, 3, 1-11.	1.5	20
36	Earlier Colorectal Cancer Screening May Be Necessary In Patients With Li-Fraumeni Syndrome. Gastroenterology, 2019, 156, 273-274.	0.6	19

#	Article	IF	CITATIONS
37	The differential diagnosis of a TP53 genetic testing result. Genetics in Medicine, 2018, 20, 806-808.	1.1	1
38	Electronic Health Record Phenotypes for Precision Medicine: Perspectives and Caveats From Treatment of Breast Cancer at a Single Institution. Clinical and Translational Science, 2018, 11, 85-92.	1.5	17
39	Returning Individual Genetic Research Results to Research Participants: Uptake and Outcomes Among Patients With Breast Cancer. JCO Precision Oncology, 2018, 2, 1-24.	1.5	15
40	Comparative clinical utility of tumor genomic testing and cell-free DNA in metastatic breast cancer. Breast Cancer Research and Treatment, 2017, 164, 627-638.	1.1	21
41	BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers. Nature Communications, 2017, 8, 319.	5.8	212
42	Allele-specific copy number estimation by whole exome sequencing. Annals of Applied Statistics, 2017, 11, 1169-1192.	0.5	8
43	Dietary influence on estrogens and cytokines in breast cancer. AIMS Molecular Science, 2017, 4, 252-270.	0.3	2
44	Evaluation of ACMG-Guideline-Based Variant Classification of Cancer Susceptibility and Non-Cancer-Associated Genes in Families Affected by Breast Cancer. American Journal of Human Genetics, 2016, 98, 801-817.	2.6	113
45	Population Frequency of Germline <i>BRCA1/2</i> Mutations. Journal of Clinical Oncology, 2016, 34, 4183-4185.	0.8	107
46	A Recurrent <i>ERCC3</i> Truncating Mutation Confers Moderate Risk for Breast Cancer. Cancer Discovery, 2016, 6, 1267-1275.	7.7	41
47	Patient feedback and early outcome data with a novel tiered-binned model for multiplex breast cancer susceptibility testing. Genetics in Medicine, 2016, 18, 25-33.	1.1	56
48	Collaborative science in the next-generation sequencing era: a viewpoint on how to combine exome sequencing data across sites to identify novel disease susceptibility genes. Briefings in Bioinformatics, 2016, 17, 672-677.	3.2	6
49	Paclitaxel is necessary for improved survival in epithelial ovarian cancers with homologous recombination gene mutations. Oncotarget, 2016, 7, 48577-48585.	0.8	6
50	Prevalence of mutations in a panel of breast cancer susceptibility genes in BRCA1/2-negative patients with early-onset breast cancer. Genetics in Medicine, 2015, 17, 630-638.	1,1	128
51	Familial Breast Cancer Risk. Current Breast Cancer Reports, 2013, 5, 170-182.	0.5	8
52	A classic presentation of an uncommon leukemia. American Journal of Hematology, 2013, 88, 431-432.	2.0	0
53	Antibodies to PCSK9. Circulation Research, 2012, 111, 274-277.	2.0	14
54	Cancer treatment according to BRCA1 and BRCA2 mutations. Nature Reviews Clinical Oncology, 2012, 9, 520-528.	12.5	69

#	Article	IF	CITATION
55	Prophylactic Mastectomy and Risk-Reducing Salpingo-oophorectomy in BRCA1/2 Mutation Carriers. Current Breast Cancer Reports, 2012, 4, 199-206.	0.5	0
56	The incidence of both serious and minor complications in young women undergoing oocyte donation. Fertility and Sterility, 2008, 90, 2165-2171.	0.5	114
57	Proprotein convertase subtilisin kexin 9: the third locus implicated in autosomal dominant hypercholesterolemia. Current Opinion in Lipidology, 2005, 16, 167-172.	1.2	78
58	Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 2069-2074.	3.3	359
59	Differential Gene Regulation of StarD4 and StarD5 Cholesterol Transfer Proteins. Journal of Biological Chemistry, 2005, 280, 19410-19418.	1.6	103
60	Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 7100-7105.	3.3	548
61	Novel putative SREBP and LXR target genes identified by microarray analysis in liver of cholesterol-fed mice. Journal of Lipid Research, 2003, 44, 2109-2119.	2.0	325
62	The spd-2 gene is required for polarization of the anteroposterior axis and formation of the sperm asters in the Caenorhabditis elegans zygote. Developmental Biology, 2000, 222, 55-70.	0.9	149